Syngene International Limited (SYNGENE.BO)
Syngene International Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Bengaluru, KA, IN. The stock last traded at $401.35, down 0.06% on the session, giving a market capitalisation of $161.19B. Its beta of 0.07 implies it has historically moved less than the broad market.
Syngene International Limited, established in 1993 and based in Bengaluru, India, functions as a prominent contract research and manufacturing organization (CRAMO). As a subsidiary of Biocon Limited, Syngene extends its comprehensive drug discovery and development solutions globally, serving clients across India, Japan, Europe, the United States, and other regions. The company's extensive offerings span the entire drug lifecycle, from early-stage research to commercial-scale production. In the discovery phase, Syngene delivers advanced chemistry services, encompassing synthetic, medicinal, computational, and analytical chemistry, as well as specialized areas like library and peptide synthesis, biomolecular science, and organic electronic materials. Its biological discovery expertise covers recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay development, drug metabolism and pharmacokinetics (DMPK), in vivo pharmacology, toxicology studies, and biologicals research. For development and manufacturing, Syngene provides support in chemical, formulation, analytical, and clinical development, alongside commercial manufacturing capabilities. They also facilitate crucial steps such as lead generation, preclinical development, active pharmaceutical ingredient (API) production, and drug product development. Their clinical services are robust, managing clinical trials, pharmacokinetic analysis, bioanalytical testing, central laboratory functions, clinical data management, regulatory submissions, biostatistics, and medical writing. Syngene's scientific proficiency integrates chemistry, biology, safety assessment, computational science, and data science. This expertise is applied across various therapeutic classes, including traditional small molecule therapeutics, biologics, and innovative modalities like peptides, oligonucleotides, antibody-drug conjugates (ADCs), and targeted degradation/stabilization technologies. The company caters to a wide array of sectors, including pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical industries. Key collaborations include partnerships with major players such as Bristol-Myers Squibb Co., Baxter Inc., and Amgen Inc.
Syngene International Limited is most often compared with the following Healthcare names: